bell potters no 1 biotech, page-36

CB - are you keeping it simple for my benefit or so as not to get in too deep for yourself, because you seem like the type of person to argue a 'why' question with the answer 'because'.

Let me help you out here a little bit more.
I will put myself in your shoes and try to explain how previous trial statistics effect NEU, as you so believe.

Here goes.

It is likely that any drug entering phase II trials will fail based on a statistical analysis of historical records.
In Neuren's case I believe the same thing is likely to occur due to the following reasons -
1.
2.
3.


Then I could retort in a balanced debate.

.....fair enough CB, but I believe the poor historical data will not correlate to NEU's chances and I believe the chances are better than historical data because of the following reasons -
1.
2.
3.


Every case is different. Add a bit of depth to your generalised points and maybe a normal discussion could be had.
Unfortunately you like to argue a point with a response equivalent of 'because'.